Table 1.
This table highlights the important clinical characteristics of all the patients who consented and were enrolled in the clinical trial.
| Baseline characteristics (n=36) | ||
|---|---|---|
| Age in years: median (range) | 59 (30–77) | |
| Sex | Female | 23 (64%) |
| Male | 13 (36%) | |
| Race | Non-Hispanic White | 19 (53%) |
| Non-Hispanic Black | 12 (33%) | |
| Hispanic | 4 (11%) | |
| Asian | 1 (3%) | |
| ECOG Performance Status | 0 | 3 (8%) |
| 1 | 32 (89%) | |
| 2 | 1 (3%) | |
| Prior treatment | Surgery | 32 (89%) |
| Chemotherapy | 36 (100%) | |
| (FOLFIRI) | 13 (37%) | |
| Bevacizumab | 9 (25%) | |
| Radiotherapy | 13 (37%) | |
| Primary site | Right colon | 10 (28%) |
| Left colon | 15 (42%) | |
| Rectal | 11 (30) | |
| Kras mutation status | G12V | 12 (33%) |
| G12D | 10 (28%) | |
| G12C | 4 (11%) | |
| G12A | 2 (6%) | |
| G13D | 2 (6%) | |
| G12’X’ | 3 (8%) | |
| G12R | 1 (3%) | |
| Q61’X’ | 1 (3%) | |
| K117N | 1 (3%) | |
“X” = unknown/not reported